MATMOR comprises two distinct operational components:

1. The front end, or pelletisation stage, relies on the Coldry Process IP, which is owned by ECT.
2. The MATMOR Retort is patented by Maddingley Technology Pty Ltd.

ECT has the exclusive world-wide rights to commercialise MATMOR, with the option to acquire the IP on agreed terms, at any time before 2014.

The Participation Agreement governing ECT’s rights and obligations expires in 2014 and requires the building of a Pilot Plant at our test facility in Bacchus Marsh, Victoria.

ECT looks forward to advancing commercialisation, fulfilling its obligations under the Participation Agreement and owning the IP outright once the appropriate stage is reached.